Date: 2015-03-19
Type of information: Nomination
Compound:
Company: Xencor (USA - CA)
Therapeutic area: Allergic diseases - Autoimmune diseases - Respiratory diseases - Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details: * On March 19, 2015, Xencor, a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced the appointment of A. Bruce Montgomery, M.D., to its Board of Directors. Dr. Montgomery has more than 25 years of drug development, operations and financing experience in the life science industry. He led development of the only three currently marketed antimicrobials for inhalation and initiated multiple other programs that have resulted in drug approvals. Currently, Dr. Montgomery serves as chief executive officer of Cardeas Pharma. Prior to that, he served four years as senior vice president of Gilead Sciences, and six years as chief executive officer of Corus Pharma, that he founded, and which was acquired by Gilead in 2006. Dr. Montgomery also served as executive vice president of research and development at PathoGenesis Corporation until its acquisition by Chiron in 2000. Dr. Montgomery received his bachelor\'s in chemistry and doctorate from the University ofWashington, Seattle. Dr. Montgomery is a board certified internist and pulmonologist.
Financial terms:
Latest news:
